Cheap Broker Fees
Moderna Inc is a biotechnology business based in the US. Moderna shares (MRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Moderna employs 1,800 staff and has a trailing 12-month revenue of around USD$7 billion.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Moderna's stock price has had significant positive movement.
Its last market close was $324.21, which is 94.38% up on its pre-crash value of $18.23 and 1,710.22% up on the lowest point reached during the March crash when the stocks fell as low as $17.91.
If you had bought $1,000 worth of Moderna stocks at the start of February 2020, those stocks would have been worth $1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $15,908.98.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$324.21|
|52-week range||$65.49 - $497.49|
|50-day moving average||$387.53|
|200-day moving average||$275.52|
|Wall St. target price||$349.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$8.46|
|1 week (2021-10-07)||N/A|
|1 month (2021-09-16)||-26.42%|
|3 months (2021-07-17)||24.85%|
|6 months (2021-04-16)||89.81%|
|1 year (2020-10-16)||338.48%|
|2 years (2019-10-18)||2,089.13%|
|3 years (2018-10-14)||N/A|
|5 years (2016-10-14)||N/A|
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, Moderna shares trade at around 38x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.9 billion.
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$7 billion|
|Operating margin TTM||54.39%|
|Gross profit TTM||$-574,877,000|
|Return on assets TTM||24.3%|
|Return on equity TTM||72.43%|
|Market capitalisation||$130.9 billion|
TTM: trailing 12 months
There are currently 14.3 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 3.8% up from 13.8 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 13.5 million). Moderna's SIR currently stands at 1.06. In other words for every 100,000 Moderna shares traded daily on the market, roughly 1060 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 40 shares are currently held short) or 0.0416% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 42 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
We're not expecting Moderna to pay a dividend over the next 12 months.
Over the last 12 months, Moderna's shares have ranged in value from as little as $65.49 up to $497.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.4941. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc. , a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co. , Inc. , Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
DeFi tokens compose a prominent sector in the cryptocurrency markets. Learn the basics of these tokens here.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.